Searched for
LEXAPRO
Single dose of antidepressant changes brainA single dose of antidepressant is enough to produce dramatic changes in the functional architecture of the human brain, scientists have fo...- What to expect from Cipla Q1 numbers due on FridayAlthough, Cipla has remained flat so far in the year 2013, analysts feel that the stock has the potential to move higher in the coming quar...
- New business model may put pressure on Cipla’s earnings in short termUnless the company significantly underperforms in the current quarter to March, it is likely to exceed the targetted growth.
- Indian pharma cos market revenue share up at 32 pcForex gains also contributed significantly to the bottom-line of many pharma companies for the quarter Q2 FY13.
- Broker's call on Tata Motors, Cipla and GSK ConsumersMorgan Stanley upgraded Tata Motors to ‘Overweight’ on hopes of a cyclical recovery in profitability of Indian auto industry.
- Need a very pragmatic pro-national drug policy: Dr YK Hamied, Cipla"It is very important for the government to take the indigenous industry seriously. We are not consulted on any issue," says Dr Hameid.
- Brokerages raise Cipla’s target price on Q2 resultsBrokerages have increased the company’s target price on expectations of better margins.
- Cipla hits 52-week high post Q2 results; Citi maintains ‘neutral’ ratingCipla surged over 3 per cent in early trade on Tuesday to hit its 52-week high of Rs 395.95 after the company reported 61 per cent jump in ...
- Cipla PAT seen up 21% led by higher other income and lower tax rate: ET NOW PollCipla is expected to report a 21 per cent jump in its net profit for the quarter ended September 30 to Rs 373 crore from Rs 309 crore repor...
- Jubilant Life's four medicines get USFDA approvalJubilant Life Sciences said it has received approvals from the US health regulator for 4 products that target CNS and CVS therapeutic areas.
- Aurobindo Pharma gets USFDA approval for anti-depressantAurobindo Pharma said it has received final approval from the US health regulator to manufacture generic version of Lexapro.
- Morgan Stanley rates Cipla overweight post AGM""Management commentary suggested that there are three more sizable product opportunities for US after Lexapro (DF supplier to Teva during ...
- Brokerages raise Cipla’s target after robust resultsPositive changes in the business model by the new management and increasing utilization of the Indore SEZ are key positives.
- Brokerages view: Coal India, Titan, JP Associates, CiplaFollowing are the recommendations of foreign brokerages on Coal India, Titan, Jaiprakash Associates and Cipla.
- Indian drug outlook favourable: ICRA & Moody'sAccording to the report, domestic formulation market size stood at Rs 58,300 crore, ranked third in terms of volume and tenth in terms of v...
- Cipla expected to report 34% gain in Q4 net profitCIPLA is expected to report a 34% YoY increase in its Q4 net profit at Rs 286 crore compared to Rs 214 crore in the year ago period, accord...
- Sun's Caraco settles litigation with Forest Lab in USThe Rs 4,300-crore Sun Pharmaceuticals Ltd's US-subsidiary, Caraco Pharmaceuticals Laboratories Ltd, has gone for settlement of the legal p...
- Sun Pharma enters pact with Forest Labs,H Lundbeck for LexaproSun Pharma and its US subsidiary Caraco Pharma have entered into agreements with Forest Laboratoriesa and H Lundbeck to settle legal procee...
- Aurobindo gets USFDA nod for anti-depressantDrug major Aurobindo Pharma on Wednesday said it has got tentative USFDA approval to market escitalopram oxalate tablets.
- Aurobindo gets USFDA approval for two generic drugsAurobindo Pharma Ltd has received tentative approval form US Food Drug Administration for perindopril erbumine tablets 2mg, 4mg, 8mg and es...
Load More
